Our pregnancy article, GLP-1s and Pregnancy Planning: What the Labels Say, stops at delivery, because that is where its labels stop. This page picks up after it. What the lactation sections of these labels say turns out to divide into three clean groups, and the grouping is genuinely surprising: the tablets restrict nursing for a reason that has nothing to do with semaglutide, one pair of injections carries real human milk measurements while the rest carry none, and a single animal figure appears in places it cannot simply be carried out of.
What follows is a reading of section 8.2 of each label, the lactation section, and nothing else. It is a map of what the labels say, not a recommendation, and it will not rank the products by how safe they look in milk, because a label does not support that reading.
What a lactation section actually is
A lactation section is written for a prescriber, not for a patient, and knowing that changes how it reads. It summarizes what is known about the medicine in milk, usually from animal studies, occasionally from a human one, and then hands the decision to the clinician. Its silence is not an approval. The absence of a prohibition means there was nothing to prohibit with, which is a statement about evidence, not about safety. Readers routinely read the absence of a restriction as a green light, and the labels do not say that anywhere.
The reverse overreading is just as common: treating the words "not recommended" as a synonym for dangerous. A label that declines to recommend something during nursing is being conservative about an unknown, which is ordinary label behavior, not a warning about a measured harm. Both directions of overreading turn a weighing instruction into a verdict, and it is not one.
The standard language: no human data, and a weighing sentence
Most of the injection labels share one structure. They state that there are no human data, report whatever animal milk data exists, and then give the same formula, product after product: "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for [the product] and any potential adverse effects on the breastfed infant from [the product] or from the underlying maternal condition." That sentence is neither permission nor a warning. It is a label telling a prescriber there is no human evidence, and that the decision must be made case by case with three things on the scale.
For Ozempic and Wegovy injections, the animal data behind that sentence is rat data: semaglutide was present in the milk of lactating rats at levels 3- to 12-fold lower than in maternal plasma, and the label itself notes that species-specific differences in lactation physiology make the clinical relevance of that unclear. That caveat deserves carrying every time an animal figure appears, and the label supplies it for you. Trulicity is the oddest entry in the whole group: no human data, and, unusually, the presence of dulaglutide in the milk of treated lactating animals was not determined. There is simply no measurement at all. Victoza and Saxenda report that liraglutide was present unchanged in lactating rat milk at concentrations approximately 50 percent of maternal plasma, and Byetta reports exenatide in the milk of lactating mice at up to 2.5 percent of maternal plasma, again with the species caveat.
Those percentages sit side by side on purpose, and the point is not to compare them. Rat milk and mouse milk are not human milk, and a ratio measured in one species does not transfer to another in any simple arithmetic, which is exactly why the labels print the caveat beside the number. The figures say what was measured. They do not say what a nursing infant receives.
The one set of human data: Mounjaro and Zepbound
Amid all the rat and mouse data, the tirzepatide labels stand out for having studied humans. The Mounjaro and Zepbound lactation sections report that in a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose.
The details are worth having verbatim, because summaries flatten them. Following a single 5 mg subcutaneous dose to 11 healthy lactating adult females, tirzepatide was undetectable in 164 of 171 milk samples, with the assay's limit of detection at 4 ng/mL, and the cumulative amount measured in the remaining 7 samples over a 28 day window was equivalent to less than 0.02 percent of the maternal administered dose. It is the most direct and most reassuring measurement anywhere in this class of labels.
And it is still a single-dose study in 11 people, which is what a label has when a label has one study. The number is allowed to be what it is: a real human measurement, a small one, and not a ranking of products. The standard weighing sentence appears on these labels too, and the existence of the study does not convert it into an instruction either way.
GLP 1 Tracker AppDoses, weights and side effect notes, all on your own device with no account and no server. A record you can hand to a prescriber, and to no one else.
Get the app
The tablets: not recommended, and not because of semaglutide
Now the finding most coverage misses. The labels for Rybelsus and Ozempic tablets, and for Wegovy tablets, say that breastfeeding is not recommended during treatment. The reason is not semaglutide. A clinical lactation study reported semaglutide concentrations below the lower limit of quantification in human breast milk; the drug itself was essentially not there. The restriction is about the other ingredient.
Oral semaglutide needs an absorption enhancer to survive the stomach, and that enhancer is called SNAC. It is what makes a semaglutide tablet possible at all. But SNAC and its metabolites are present in human milk, and the labels reason it out: because the activity of enzymes involved in SNAC clearance may be lower in infants compared to adults, higher SNAC plasma levels may occur in neonates and infants, and because of the unknown potential for serious adverse reactions due to possible accumulation, and because there are alternative semaglutide products that do not contain SNAC and can be used during lactation, patients are advised that breastfeeding is not recommended during treatment.
That is a remarkable sentence once it is laid out. The medicine was essentially absent from milk, the restriction attaches to the delivery ingredient, and the label's own logic includes the existence of an alternative. It also means the tablet rules and the injection rules genuinely differ during nursing, which is one more way the two forms of semaglutide are not interchangeable lists, a theme of Wegovy Tablets: What Changes When Semaglutide Is a Pill.
Foundayo, and how to read all of this
Foundayo, the oral orforglipron product, sits in the third group: not recommended, on animal data. There are no human data, orforglipron was present in the milk of lactating rats, and the label reasons that when a drug is present in animal milk, it is likely that the drug will be present in human milk. On that basis the label states that FOUNDAYO is not recommended for nursing women. The product is covered in full in Foundayo (Orforglipron): The Daily GLP-1 Pill, Explained.
Read together, the three groups say one thing clearly: this is a case-by-case evidence landscape, and the labels are built to hand it to clinicians rather than to settle it in print. The tirzepatide data is small and real, the semaglutide injection data is absent and animal, the tablet restriction is about an absorption enhancer, and the Foundayo restriction rests on a likelihood argument from rats. None of that ranks the products, and nobody should leave this page with a ranking.
Someone already nursing and already taking one of these medicines needs one sentence, not a plan: this is a conversation to have with the prescriber and, where there is one, the infant's clinician. Not as an emergency, and not with an instruction to stop anything. Just the same weighing the labels describe, done by the people in a position to do it, with the same sections this article has summarized open in front of them. The broader picture of this class and its approved uses is in What GLP-1s Are Actually Approved to Treat.
Frequently asked questions
Is it safe to breastfeed while taking Ozempic or Wegovy injections?
The label does not answer that question with a yes or a no. There are no human data on semaglutide in breast milk, and the lactation section says the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need and any potential adverse effects on the infant. That weighing sentence is addressed to a prescriber, not a verdict, and this decision belongs to the person and the clinicians who know them.
Why do the semaglutide tablets say breastfeeding is not recommended when the injections do not?
Because of SNAC, the absorption enhancer that lets a semaglutide tablet survive the stomach. A clinical lactation study reported semaglutide itself below the lower limit of quantification in human milk, but SNAC and its metabolites are present in human milk, and the enzymes that clear SNAC may be less active in infants, raising the possibility of accumulation. Because there are semaglutide injections without SNAC, the label advises that breastfeeding is not recommended during treatment with the tablets.
Does tirzepatide get into breast milk?
A single-dose clinical lactation study behind the Mounjaro and Zepbound labels found the concentration of tirzepatide in breast milk to be either undetectable or low compared with the maternal dose. Following one 5 mg dose to 11 healthy lactating adults, tirzepatide was undetectable in 164 of 171 milk samples, and the total in the remaining 7 over 28 days was under 0.02 percent of the maternal dose. It is the most direct human measurement in the class and still a single-dose study in 11 people.
What does Foundayo's label say about nursing?
That there are no human data, that orforglipron was present in the milk of lactating rats, and that when a drug is present in animal milk it is likely to be present in human milk. On that basis the label states that Foundayo is not recommended for nursing women. It is the animal-data version of a restriction, and animal milk figures do not transfer to humans in a simple ratio, a caveat two of these labels state themselves.
I am nursing and already taking a GLP-1. What should I do?
Have the conversation with your prescriber and, where there is one, your infant's clinician. That is the entire instruction, and it is not an emergency. Nothing in any lactation section tells a person to stop nursing or to stop a medicine; each one hands the weighing to the clinicians who know the person. Bring the questions you actually have and let them read the same sections this article summarizes.